Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial

Background: Rates of adverse events with sorafenib were higher in the DECISION trial in radioactive iodine-refractory, advanced differentiated thyroid cancer (DTC) than in trials of sorafenib for other tumor types. One possible explanation is that sarcopenia, a known predictive factor of toxicity in...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Thyroid
Hlavní autoři: Huillard, Olivier, Jouinot, Anne, Tlemsani, Camille, Brose, Marcia S., Arrondeau, Jennifer, Meinhardt, Gerold, Fellous, Marc, De Sanctis, Yoriko, Schlumberger, Martin, Goldwasser, Francois
Médium: Artigo
Jazyk:Inglês
Vydáno: Mary Ann Liebert, Inc., publishers 2019
Témata:
Thyroid Cancer and Nodules
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6918875/
https://ncbi.nlm.nih.gov/pubmed/31860408
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2018.0784
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky